Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of reportable segment net income (loss)

The Company's reportable segment net income (loss) for the years ended December 31, 2024, 2023 and 2022, consisted of the following:

	Year Ended December 31,
	2024			2023			2022
Significant segment expenses:
Live biotherapeutics platform	$	29,006		$	43,342		$	34,764
SER-155		6,804			7,759			5,069
R&D personnel-related (including stock-based compensation)		28,689			65,251			68,059
G&A personnel-related (including stock-based compensation)		22,679			36,069			30,653
Professional fees		9,805			18,784			23,529
Facility-related and other		20,699			22,647			16,081
Other segment expense (income) (1)		8,089			(3,722	)		5,426
Net loss from continuing operations		(125,771	)		(190,130	)		(183,581	)
Net income (loss) from discontinued operations, net of tax (2)		125,907			76,406			(66,576	)
Net income (loss)	$	136		$	(113,724	)	$	(250,157	)

[1] Other segment (expense) income includes research and development expenses on early stage programs, manufacturing services expenses, gain on sale of VOWST Business, interest income and other (expense) income, net.

[2] See Note 3, Discontinued Operations and TSA, for further details.